DMD DiLab, Inc.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xiao, L.
Right arrow Articles by Cheng, K.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xiao, L.
Right arrow Articles by Cheng, K.-C.

Vol. 30, Issue 9, 951-956, September 2002

Insights from a Three-Dimensional Model into Ligand Binding to Constitutive Active Receptor

Li Xiao, Xiaoming Cui, Vincent Madison, Ronald E. White, and K.-C. Cheng

Department of Structural Chemistry (L.X., V.M.) and Department of Exploratory Drug Metabolism (X.C., R.E.W., K.-C.C), Schering-Plough Research Institute, Kenilworth, New Jersey

Two orphan nuclear receptors, constitutive active (or androstane) receptor (CAR) and pregnane X receptor (PXR), are among the most important mediators of ligand-activated transcriptional induction of liver microsomal cytochrome P450 drug-metabolizing enzymes. CAR and PXR belong to the same NR1I receptor subfamily and show high sequence homology to each other. The vitamin D receptor (VDR) also belongs to the NR1I subfamily and has the second highest homology to CAR in the ligand binding domain. A 3D model of the ligand binding domain of human CAR (hCAR) was constructed based on the available X-ray structures of human PXR (hPXR) and VDR (hVDR). The model shows that the size of the ligand binding cavities of hCAR and hPXR are similar, but larger than that of hVDR. hPXR's capability of binding to extremely large ligands, such as rifampicin, implies that its binding cavity may be able to expand further through the flexibility of a surface loop. In contrast, hCAR does not have this loop so that its cavity cannot expand, suggesting that hCAR would not bind to the largest hPXR ligands. Docking calculations of selected ligands to hCAR, based on the structural model, are consistent with previously reported receptor binding data. The results from this study indicate that structural modeling will be a useful tool for understanding ligand binding to hCAR and for design of drugs free of hCAR-mediated enzyme induction.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
S. Ekins, E. Kirillov, E. A. Rakhmatulin, and T. Nikolskaya
A NOVEL METHOD FOR VISUALIZING NUCLEAR HORMONE RECEPTOR NETWORKS RELEVANT TO DRUG METABOLISM
Drug Metab. Dispos., March 1, 2005; 33(3): 474 - 481.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Xia and B. Kemper
Structural Determinants of Constitutive Androstane Receptor Required for Its Glucocorticoid Receptor Interacting Protein-1-mediated Nuclear Accumulation
J. Biol. Chem., February 25, 2005; 280(8): 7285 - 7293.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
K. Swales and M. Negishi
CAR, Driving into the Future
Mol. Endocrinol., July 1, 2004; 18(7): 1589 - 1598.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
H. Jinno, T. Tanaka-Kagawa, N. Hanioka, S. Ishida, M. Saeki, A. Soyama, M. Itoda, T. Nishimura, Y. Saito, S. Ozawa, et al.
Identification of Novel Alternative Splice Variants of Human Constitutive Androstane Receptor and Characterization of Their Expression in the Liver
Mol. Pharmacol., March 1, 2004; 65(3): 496 - 502.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
C. Handschin and U. A. Meyer
Induction of Drug Metabolism: The Role of Nuclear Receptors
Pharmacol. Rev., December 1, 2003; 55(4): 649 - 673.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.